Lambert-Eaton myasthenic syndrome (LEMS) is an
autoimmune disease of the neuromuscular junction. Approximately 50-60% of patients with LEMS have a
tumor, most often
small cell lung cancer (SCLC), making LEMS a paraneoplastic neurological syndrome. In Japan, the clinical picture is a male: female ratio of 3:1; mean age, 62 years (17-80 years); and 61% of LEMS patients have SCLC (SCLC-LEMS), with the remainder of patients having no
cancer. Patients with LEMS develop a unique set of clinical characteristics, which include proximal
muscle weakness, depressed tendon reflexes with post-tetanic potentiation, and autonomic symptoms. Interestingly, less than 10% of patients with LEMS have
cerebellar ataxia (LEMS with
paraneoplastic cerebellar degeneration). Considering its pathomechanisms, LEMS is a presynaptic disorder of neuromuscular transmission in which quantal release of
acetylcholine is impaired by
autoantibodies against P/Q-type voltage-gated
calcium channels (P/Q-VGCCs) at active zones reducing quantal release of
acetylcholine, although an animal model using immunization with purified P/Q-VGCCs has not yet been established. The diagnosis can be confirmed by finding a reduced compound muscle action potential amplitude that increases by over 60% following maximum voluntary activation or 50 Hz nerve stimulation. Approximately 90% of patients who satisfy the above electrophysiological diagnostic criteria are positive for P/Q-VGCC
antibodies have their diagnosis confirmed. Specific
tumor therapy in SCLC-LEMS will often improve the
neurologic deficit.
Tumor removal is the primary treatment for LEMS. If primary
tumor screening is negative, screening should be repeated after 3-6 months, followed by screening every 6 months until 2 years post diagnosis. Most patients benefit from
3,4-diaminopyridine being administered with
pyridostigmine. In those with severe weakness, high-dose intravenous
gamma-globulin (
IVIg) or
plasmapheresis confers short-term benefits.
Prednisone, alone or combined with immunosuppressive drugs, can achieve long-term control of the disorder. The results of a prospective cohort study showed that the presence of LEMS with SCLC had a significant survival advantage independent of other prognostic factors including disease extent, age, sex, performance status, and serum
sodium values.